I. Gilloteau

发表

Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long‐Term Results of Two Phase III Randomized Controlled Trials

V. Strand, A. Deodhar, P. Conaghan, 2020, Arthritis care & research.

Dose increase beyond labelled dose of biologics is associated with incremental pharmacy costs: results from a real-world study in the UK

A. Bewley, H. Tian, C. Miglio, 2018, The Journal of dermatological treatment.

A multidimensional assessment of the burden of psoriasis: results from a multinational dermatologist and patient survey

L. Naldi, S. Jo, R. Romiti, 2018, The British journal of dermatology.

Evaluating the cost-effectiveness of secukinumab in moderate-to-severe psoriasis: a Japanese perspective

C. Graham, A. Igarashi, A. Igarashi, 2018, Journal of medical economics.

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)

M. Lebwohl, A. Blauvelt, J. Bagel, 2018, Dermatology and Therapy.

Secukinumab sustains good efficacy and favourable safety in moderate‐to‐severe psoriasis after up to 3 years of treatment: results from a double‐blind extension study

T. Luger, U. Mrowietz, R. Bissonnette, 2017, The British journal of dermatology.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Effect of secukinumab on quality of life and psoriasis‐related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52‐week study

Yang Zhao, A. Gottlieb, M. Lebwohl, 2017, Journal of the American Academy of Dermatology.

Incremental burden of cardiovascular comorbidity and psoriatic arthritis among adults with moderate‐to‐severe psoriasis in five European countries

M. Augustin, J. Vietri, H. Tian, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

Predictors Of Utility Over Time Among Patients With Treatment-Naïve Advanced Melanoma From The Phase 3 Checkmate 066 Trial.

A. Briggs, A. Exuzides, C. Colby, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Exploring determinants of psoriasis patients’ treatment choices: a discrete-choice experiment study in the United States and Germany

S. Feldman, M. Boeri, C. Poulos, 2021, The Journal of dermatological treatment.

Disease Burden and Treatment Patterns of Psoriasis in Russia: A Real-World Patient and Dermatologist Survey

E. Novoderezhkina, H. Tian, G. Pietri, 2018, Dermatology and Therapy.

Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study.

H. Groen, R. Heist, J. Wolf, 2022, European journal of cancer.

Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from the CLEAR study

F. Vanaclocha, K. Reich, A. Blauvelt, 2017, Journal of the European Academy of Dermatology and Venereology : JEADV.

The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial

L. Coates, D. Gladman, V. Strand, 2022, The Lancet Rheumatology.

Measurement of adherence to BCR-ABL inhibitor therapy in chronic myeloid leukemia: current situation and future challenges

B. Vrijens, L. Noens, M. Hensen, 2014, Haematologica.

Psoriasis: clinical and epidemiological features and therapy issues

G. Pietri, A. Bakulev, I. Gilloteau, 2018, Vestnik dermatologii i venerologii.

Quantifying the burden of informal caregiving for patients with cancer in Europe

Michael Lees, A. Goren, Amir Goren, 2014, Supportive Care in Cancer.

Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75–89 response: results from two phase 3 studies of secukinumab

B. Strober, A. Gnanasakthy, M. Mordin, 2017, The Journal of dermatological treatment.

Patient–dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real‐world multinational survey

L. Naldi, S. Jo, R. Romiti, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study

A. Abernethy, K. Savage, P. Ascierto, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Caring for relatives with lung cancer in Europe: an evaluation of caregivers’ experience

Jacek Jassem, J. Jassem, J. Penrod, 2015, Quality of Life Research.

Quality of survival: a new concept framework to assess the quality of prolonged life in cancer

L. Fallowfield, G. Lyman, E. Nadler, 2017 .

Quantifying the Burden of Caregiving for Patients with Cancer in Europe

A. Mori, I. Gilloteau, A. Goren, 2012 .

Secukinumab significantly reduces psoriasis‐related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom

R. Warren, C. Graham, L. Miles, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Rapid Relief From Itching and Pain in Patients with Moderate-to-Severe Psoriasis : Patient Symptom Diary Data from Two Phase 3 , Randomized , Placebo-controlled Clinical Trials

B. Elewski, G. Yosipovitch, J. Weiss, 2019 .

Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis

Yang Zhao, D. Stull, A. Finlay, 2018, The British journal of dermatology.

Secukinumab sustains early patient‐reported outcome benefits through 1 year: Results from 2 phase III randomized placebo‐controlled clinical trials comparing secukinumab with etanercept

B. Strober, A. Gnanasakthy, L. McLeod, 2017, Journal of the American Academy of Dermatology.

Higher Psoriasis Skin Clearance Is Associated with Lower Annual Indirect Costs in the United States: A Post Hoc Analysis from the CLEAR Study

Yang Zhao, S. Feldman, C. Graham, 2018, Journal of managed care & specialty pharmacy.

A multidimensional overview of the burden of psoriasis

L. Naldi, S. Jo, R. Romiti, 2018, British Journal of Dermatology.

Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study.

K. Reich, A. Blauvelt, K. Kingo, 2019, Journal of the American Academy of Dermatology.

Sleep Problems in Patients with Rheumatoid Arthritis

R. Westhovens, K. Van der Elst, I. Gilloteau, 2014, The Journal of Rheumatology.

Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States.

S. Feldman, D. Cella, S. Regnier, 2019, Journal of the American Academy of Dermatology.

Economic burden of comorbidities in psoriasis patients in the United States: results from a retrospective U.S. database

S. Feldman, H. Tian, P. Mollon, 2017, BMC Health Services Research.

Cost‐effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany

M. Augustin, C. Graham, C. O’Neill, 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.

Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.

A. Mansfield, J. Neal, R. Heist, 2023, Clinical lung cancer.

Secukinumab Provides Rapid Relief From Itching and Pain in Patients With Moderate-to-Severe Psoriasis: Patient Symptom Diary Data From Two Phase 3, Randomized, Placebo-Controlled Clinical Trials.

B. Elewski, G. Yosipovitch, J. Weiss, 2019, Acta dermato-venereologica.